https://scholars.lib.ntu.edu.tw/handle/123456789/641200
標題: | Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial | 作者: | Danese, Silvio Panaccione, Remo Feagan, Brian G Afzali, Anita Rubin, David T Sands, Bruce E Reinisch, Walter Panés, Julián Sahoo, Aparna Terry, Natalie A Chan, Daphne Han, Chenglong Frustaci, Mary Ellen Yang, Zijiang Sandborn, William J Hisamatsu, Tadakazu Andrews, Jane M D'Haens, Geert R SHU-CHEN WEI |
公開日期: | 二月-2024 | 卷: | 9 | 期: | 2 | 起(迄)頁: | 133 | 來源出版物: | The lancet. Gastroenterology & hepatology | 摘要: | Many patients with moderately to severely active Crohn's disease do not respond to available therapies or lose response over time. The GALAXI-1 study previously found that three intravenous guselkumab dosages showed superior clinical and endoscopic outcomes over placebo at week 12 in patients with moderately to severely active Crohn's disease. We report the safety and efficacy of subcutaneous guselkumab maintenance regimens to week 48 in the GALAXI-1 study. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/641200 | ISSN: | 24681253 | DOI: | 10.1016/S2468-1253(23)00318-7 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。